TABLE 4.
Baseline variables associated with retention at 6 and 12 months of treatment
| Baseline Variable | % Completed 6 Months | Unadjusted HR1 (95% CI3) |
Adjusted HR2 (95% CI3) |
% Completed 12 Months | Unadjusted HR1 (95% CI3) |
Adjusted HR2 (95% CI3) |
|---|---|---|---|---|---|---|
| Age | ||||||
| ≤38 | 67 | 1.27 (0.85–1.90) | 1.52 (0.87–2.66) | 47 | 1.22 (0.89–1.67) | 1.53 (1.02–2.29)6 |
| >38 | 73 | 54 | ||||
| Gender | ||||||
| Female | 70 | 0.92 (0.61–1.37) | 1.64 (0.88–3.06) | 53 | 1.10 (0.81–1.50) | 1.55 (0.99–2.42) |
| Male | 71 | 49 | ||||
| Race | ||||||
| African American | 67 | 1.42 (0.93–2.16) | 1.18 (0.68–2.05) | 48 | 0.82 (0.60–1.13) | 1.00 (0.67–1.48) |
| White | 75 | 55 | ||||
| Employment | ||||||
| Employed | 88 | 3.36 (1.69–6.67) | 3.30 (1.36–8.02) | 64 | 1.81 (1.20–2.74) | 1.49 (0.91–2.45) |
| Unemployed | 65 | 47 | ||||
| Referral source | ||||||
| SEP4 | 57 | 1.92 (1.26–2.90) | 1.39 (0.61–2.04) | 35 | 1.88 (1.35–2.62) | 1.23 (0.78–1.94) |
| Other5 | 75 | 56 | ||||
| Days of heroin use in month prior to intake | ||||||
| 0–29 days | 80 | 2.00 (1.28–3.12) | 2.19 (1.13–4.23) | 63 | 1.87 (1.34–2.61) | 1.47 (0.93–2.32) |
| 30 days | 64 | 42 | ||||
| Days of cocaine use in month prior to intake | ||||||
| 0–29 days | 74 | 1.98 (1.22–3.22) | 1.05 (0.55–2.01) | 56 | 2.40 (1.65–3.49) | 1.71 (1.05–2.77) |
| 30 days | 55 | 23 | ||||
| Days of injecting drugs in month prior to intake | ||||||
| 0 days | 79 | 1.70 (1.03–2.82) | 1.45 (0.69–3.06) | 66 | 1.95 (1.31–2.89) | 1.72 (1.00–2.96) |
| 1–30 days | 67 | 44 | ||||
1
Unadjusted Hazard Ratio
2
Adjusted for baseline variables
3
CI: Confidence Interval
4
SEP: Referral from Syringe Exchange Program
5
Other: Referral source other than SEP
6
Bolded text indicates statistically significant relationship